open access

Vol 25, No 3 (2020)
Reviews
Published online: 2020-05-01
Submitted: 2019-08-16
Get Citation

Prostatic irradiation-induced sexual dysfunction: a review and multidisciplinary guide to management in the radical radiotherapy era (Part I defining the organ at risk for sexual toxicities)

Marigdalia K. Ramirez-Fort, Marc J. Rogers, Roberto Santiago, Sean S. Mahase, Melissa Mendez, Yi Zheng, Xiang Kong, James A. Kashanian, M. Junaid Niaz, Shearwood McClelland, Xiaodong Wu, Neil H. Bander, Peter Schlegel, John P. Mulhall, Christopher S. Lange
DOI: 10.1016/j.rpor.2020.03.007
·
Rep Pract Oncol Radiother 2020;25(3):367-375.

open access

Vol 25, No 3 (2020)
Reviews
Published online: 2020-05-01
Submitted: 2019-08-16

Abstract

Prostate cancer is the most common malignancy and the second leading cause of cancer-related death in men. Radiotherapy is a curative option that is administered via external beam radiation, brachytherapy, or in combination. Erectile, ejaculatory and orgasm dysfunction(s) is/are known potential and common toxicities associated with prostate radiotherapy. Our multidisciplinary team of physicians and/or scientists have written a three (3) part comprehensive review of the pathogenesis and management radiation-induced sexual dysfunction. Part I reviews pertinent anatomy associated with normal sexual function and then considers the pathogenesis of prostate radiation-induced sexual toxicities. Next, our team considers the associated radiobiological (including the effects of time, dose and fractionation) and physical (treatment planning and defining a novel Organ at Risk (OAR)) components that should be minded in the context of safe radiation treatment planning. The authors identify an OAR (i.e., the prostatic plexus) and provide suggestions on how to minimize injury to said OAR during the radiation treatment planning process.

Abstract

Prostate cancer is the most common malignancy and the second leading cause of cancer-related death in men. Radiotherapy is a curative option that is administered via external beam radiation, brachytherapy, or in combination. Erectile, ejaculatory and orgasm dysfunction(s) is/are known potential and common toxicities associated with prostate radiotherapy. Our multidisciplinary team of physicians and/or scientists have written a three (3) part comprehensive review of the pathogenesis and management radiation-induced sexual dysfunction. Part I reviews pertinent anatomy associated with normal sexual function and then considers the pathogenesis of prostate radiation-induced sexual toxicities. Next, our team considers the associated radiobiological (including the effects of time, dose and fractionation) and physical (treatment planning and defining a novel Organ at Risk (OAR)) components that should be minded in the context of safe radiation treatment planning. The authors identify an OAR (i.e., the prostatic plexus) and provide suggestions on how to minimize injury to said OAR during the radiation treatment planning process.

Get Citation

Keywords

Prostate cancer; Erectile dysfunction; Ejaculatory dysfunction; Orgasmic dysfunction; Radiation therapy; Organ at risk

About this article
Title

Prostatic irradiation-induced sexual dysfunction: a review and multidisciplinary guide to management in the radical radiotherapy era (Part I defining the organ at risk for sexual toxicities)

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 25, No 3 (2020)

Pages

367-375

Published online

2020-05-01

DOI

10.1016/j.rpor.2020.03.007

Bibliographic record

Rep Pract Oncol Radiother 2020;25(3):367-375.

Keywords

Prostate cancer
Erectile dysfunction
Ejaculatory dysfunction
Orgasmic dysfunction
Radiation therapy
Organ at risk

Authors

Marigdalia K. Ramirez-Fort
Marc J. Rogers
Roberto Santiago
Sean S. Mahase
Melissa Mendez
Yi Zheng
Xiang Kong
James A. Kashanian
M. Junaid Niaz
Shearwood McClelland
Xiaodong Wu
Neil H. Bander
Peter Schlegel
John P. Mulhall
Christopher S. Lange

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl